Abstract
Psychiatric disorders have a strong heritability, and like most common disorders many gene variants, each with a small effect yize , contribute to the genetic risk. One of the challenges in complex genetics is to determine how different alleles interact with each other and with the environment in the context of disease etiology. Here we discuss mouse models that resemble aspects of syndromes of human psychiatric disorders, with particular emphasis on depression and drug addiction. These disorders rank among the top 10 causes of disability and morbidity worldwide and often occur together, thus resulting in a greater severity of health-related consequences. Mice have become the premier research organism, due to their excellent genetics. We have a large and ever-increasing number of mouse strains with defined genetic backgrounds, and the possibilities of precise genetic manipulations seem almost unlimited. Furthermore, environmental factors that are thought to influence disease outcome can be controlled, thus enabling researchers to study interactions between genes and the environment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CMS:
-
Chronic mild stress
- Cnr1:
-
Cannabinoid receptor 1
- CPP:
-
Conditioned place preference
- DMS:
-
Diagnostic and Statistical Manual of Mental Disorders
- DNA:
-
Deoxyribonucleic acid
- F1:
-
First filial generation
- FST:
-
Forced swim test
- kHz:
-
Kilohertz
- OB:
-
Olfactory bulbectomy
- PR:
-
Progressive ratio
- QTL:
-
Quantitative trait loci
- RI:
-
Recombinant inbred
- SSR:
-
Simple sequence repeats
- SSRIs:
-
Selective serotonin reuptake inhibitors
- STR:
-
Short tandem repeats
- TST:
-
Tail suspension test
- USV:
-
Ultrasonic vocalisation
- VNTR:
-
Variable number tandem repeats
References
Abuin A, Hansen GM, Zambrowicz B (2007) Gene trap mutagenesis. Handb Exp Pharmacol:129–147.
Arguello PA, Gogos JA (2006) Modeling madness in mice: one piece at a time. Neuron 52:179–196.
Aronoff R, Petersen CC (2006) Controlled and localized genetic manipulation in the brain. J Cell Mol Med 10:333–352.
Association AP (1994) DSM IV – Diagnostic and statistical manual of psychiatric disorders, 4th Edition. American Psychiatric Association.Washington, DC:
Belknap JK, Hitzemann R, Crabbe JC, Phillips TJ, Buck KJ, Williams RW (2001) QTL analysis and genomewide mutagenesis in mice: complementary genetic approaches to the dissection of complex traits. Behav Genet 31:5–15.
Bell IR, Hardin EE, Baldwin CM, Schwartz GE (1995) Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities. Environ Res 70:84–97.
Bennett B, Downing C, Parker C, Johnson TE (2006) Mouse genetic models in alcohol research. Trends Genet 22:367–374.
Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94:147–160.
Branchi I, Santucci D, Vitale A, Alleva E (1998) Ultrasonic vocalizations by infant laboratory mice: a preliminary spectrographic characterization under different conditions. Dev Psychobiol 33:249–256.
Brault V, Pereira P, Duchon A, Herault Y (2006) Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization. PLoS Genet 2:e86.
Caldarone BJ, George TP, Zachariou V, Picciotto MR (2000) Gender differences in learned helplessness behavior are influenced by genetic background. Pharmacol Biochem Behav 66:811–817.
Carboni E, Vacca C (2003) Conditioned place preference. A simple method for investigating reinforcing properties in laboratory animals. Methods Mol Med 79:481–498.
Cryan JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatr 9:326–357.
Dalvi A, Lucki I (1999) Murine models of depression. Psychopharmacology (Berl) 147:14–16.
de Paulis T (2007) Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 10:193–201.
de Wit H, Stewart J (1981) Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 75:134–143.
Dierich A, Kieffer BL (2004) Knockout mouse models in pain research. Methods Mol Med 99:269–299.
Drews E, Schneider M, Koch M (2005) Effects of the cannabinoid receptor agonist win 55,212–2 on operant behavior and locomotor activity in rats. Pharmacol Biochem Behav 80:145–150.
Eberle MA, Ng PC, Kuhn K, Zhou L, Peiffer DA, Galver L, Viaud-Martinez KA, Lawley CT, Gunderson KL, Shen R, Murray SS (2007) Power to detect risk alleles using genome-wide tag SNP panels. PLoS Genet 3:1827–1837.
Fan JB, Chee MS, Gunderson KL (2006) Highly Parallel genomic assays. Nat Rev Genet 7:632–644.
Flint J (2003) Analysis of quantitative trait loci that influence animal behavior. J Neurobiol 54:46–77.
France CP, Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937–943.
Gaveriaux-Ruff C, Kieffer BL (2007) Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases. Pharmacol Ther 113:619–634.
Gellert VF, Sparber SB (1977) A comparison of the effects of naloxone upon body weight loss and suppression of fixed-ratio operant behavior in morphine-dependent rats. J Pharmacol Exp Ther 201:44–54.
Hansson AC, Bermudez-Silva FJ, Malinen H, Hyytia P, Sanchez-Vera I, Rimondini R, Rodriguez de Fonseca F, Kunos G, Sommer WH, Heilig M (2007) Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32:117–126.
Jarosik J, Legutko B, Unsicker K, von Bohlen und Halbach O (2007) Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 204:20–28.
Jentsch JD, Henry PJ, Mason PA, Merritt JH, Ziriax JM (1998) Establishing orally self-administered cocaine as a reinforcer in rats using home-cage pre-exposure. Prog Neuropsychopharmacol Biol Psychiatr 22:229–239.
Katz RJ (1982) Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav 16:965–968.
Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299–316.
Koob GF, Caine SB, Parsons L, Markou A, Weiss F (1997) Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 57:513–521.
Kosten TR, O’Connor PG (2003) Management of drug and alcohol withdrawal. N Engl J Med 348:1786–1795.
Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315–322.
Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. Jama 278:144–151.
McArthur R, Borsini F (2006) Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 84:436–452.
Meisch RA, Lemaire GA, Cutrell EB (1992) Oral self-administration of pentobarbital by rhesus monkeys: relative reinforcing effects under concurrent signalled differential-reinforcement-of-low-rates schedules. Drug Alcohol Depend 30:215–225.
Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818–827.
Murray CJL, Lopez AD (1996) Evidence-based health policy – Lessons from the global burden of disease study. Science 274:740–743.
Nelson JC, Charney DS (1981) The symptoms of major depressive illness. Am J Psychiatr 138:1–13.
Otmakhova NA, Gurevich EV, Katkov YA, Nesterova IV, Bobkova NV (1992) Dissociation of multiple behavioral effects between olfactory bulbectomized C57Bl/6J and DBA/2J mice. Physiol Behav 52:441–448.
Overmier JB, Seligman ME (1967) Effects of inescapable shock upon subsequent escape and avoidance responding. J Comp Physiol Psychol 63:28–33.
Palomo T, Archer T, Kostrzewa RM, Beninger RJ (2007) Comorbidity of substance abuse with other psychiatric disorders. Neurotox Res 12:17–27.
Papp M, Moryl E, Willner P (1996) Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129–136.
Paterson NE, Markou A (2007) Animal models and treatments for addiction and depression co-morbidity. Neurotox Res 11:1–32.
Pfeifer A (2006) Lentiviral transgenesis – a versatile tool for basic research and gene therapy. Curr Gene Ther 6:535–542.
PhillipsTJ (1997) Behavior genetics of drug sensitization. Crit Rev Neurobiol 11:21–33.
Pinkston JW, Branch MN (2003) Sensitization to cocaine in pigeons: interaction with an operant contingency. Exp Clin Psychopharmacol 11:102–109.
Porsolt RD, Bertin A, Jalfre M (1977a) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336.
Porsolt RD, Le Pichon M, Jalfre M (1977b) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730–732.
Ristevski S (2005) Making better transgenic models: conditional, temporal, and spatial approaches. Mol Biotechnol 29:153–163.
Robbins PR (1974) Depression and drug addiction. Psychiatr Q 48:374–386.
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157–198.
Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 Suppl. 2:S91–S117.
Ropers HH (2007) New perspectives for the elucidation of genetic disorders. Am J Hum Genet 81:199–207.
Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98:1912–1917.
Sarter M, Bruno J (2002) Animal models in biological psychiatry. In: D’Haenen H, Den Boer H, Willner P, eds. Textbook of Biological Psychiatry Wiley.Chichester:
Scattoni ML, McFarlane HG, Zhodzishsky V, Caldwell HK, Young WS, Ricceri L, Crawley JN (2007) Reduced ultrasonic vocalizations in vasopressin 1b knockout mice. Behav Brain Res.
Schmidt-Supprian M, Rajewsky K (2007) Vagaries of conditional gene targeting. Nat Immunol 8:665–668.
Schulteis G, Markou A, Cole M, Koob GF (1995) Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92:5880–5884.
Self DW, Nestler EJ (1995) Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463–495.
Seligman ME, Beagley G (1975) Learned helplessness in the rat. J Comp Physiol Psychol 88:534–541.
Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118–130.
Sieberts SK, Schadt EE (2007) Moving toward a system genetics view of disease. Mamm Genome 18:389–401.
Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627–647.
Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD (1987) The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatr 11:659–671.
Stewart BS, Lemaire GA, Roache JD, Meisch RA (1994) Establishing benzodiazepines as oral reinforcers: midazolam and diazepam self-administration in rhesus monkeys. J Pharmacol Exp Ther 271:200–211.
Stinus L, Caille S, Koob GF (2000) Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology (Berl) 149:115–120.
Takao K, Yamasaki N, Miyakawa T (2007) Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders. Neurosci Res 58:124–132.
Tsankova N, Renthal W, Kumar A, Nestler EJ (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8:355–367.
Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) Paradigm: update of the last decade. Addict Biol 12:227–462.
Wahlsten D, Rustay NR, Metten P, Crabbe JC (2003) In search of a better mouse test. Trends Neurosci 26:132–136.
Watson WP, Little HJ (1999) Correlation between increases in dihydropyridine binding in vivo and behavioural signs of ethanol withdrawal in mice. Alcohol Alcohol 34:35–42.
Watson WP, Misra A, Cross AJ, Green AR, Little HJ (1994) The differential effects of felodipine and nitrendipine on cerebral dihydropyridine binding ex vivo and the ethanol withdrawal syndrome in mice. Br J Pharmacol 112:1017–1024.
Willner P (1995) Animal-models of depression – validity and applications. Depression and Mania 49:19–41.
Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90–110.
Willner P, Mitchell PJ (2002) The validity of animal models of predisposition to depression. Behav Pharmacol 13:169–188.
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93:358–364.
Winslow JT, Hearn EF, Ferguson J, Young LJ, Matzuk MM, Insel TR (2000) Infant vocalization, adult aggression, and fear behavior of an oxytocin null mutant mouse. Horm Behav 37:145–155.
Wolgin DL, Hertz JM (1995) Effects of acute and chronic cocaine on milk intake, body weight, and activity in bottle- and cannula-fed rats. Behav Pharmacol 6:746–753.
Wurbel H (2002) Behavioral phenotyping enhanced--beyond (environmental) standardization. Genes Brain Behav 1:3–8.
Zhang F, Aravanis AM, Adamantidis A, de Lecea L, Deisseroth K (2007) Circuit-breakers: optical technologies for probing neural signals and systems. Nat Rev Neurosci 8:577–581.
Zueger M, Urani A, Chourbaji S, Zacher C, Roche M, Harkin A, Gass P (2005) Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 374:142–146.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Drews, E., Becker, A., Bilkei-Gorzo, A., Zimmer, A. (2008). Animal Models of Affective Behaviors and Drug Addiction. In: Turck, C. (eds) Biomarkers for Psychiatric Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-79251-4_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-79251-4_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-79250-7
Online ISBN: 978-0-387-79251-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)